PCI device useful for IOL calculations

Article

A partial coherence interferometry (PCI) device has been found to be a valid tool for calculating toric intraocular lenses (IOL) in a recently published study.

A partial coherence interferometry (PCI) device has been found to be a valid tool for calculating toric intraocular lenses (IOL) in a recently published study.

Dr Mark A. Bullimore et al. (University of Houston, Texas, USA) examined the agreement between the IOLMaster 500 PCI device (Carl Zeiss Meditec) and the Marco 1-position manual keratometer (prospectively) and the Javal 2-position manual keratometer (retrospectively). Additionally, the repeatability of the PCI device was assessed.

When comparing the PCI device with the 1-position keratometer, the team found that the axis was within 5 degrees in 72.1% of eyes. There was a slight difference in the cyclinder power and the mean power of 0.18 D and 0.33 D respectively. The comparison of the PCI and the 2-position keratometer demonstrated similar results for the axis, which was within 5 degrees for 77.1% of eyes. The cylinder power was nearly the same, however the difference in mean power was 0.34 D. It was found that the repeatability of the PCI device was better than both manual options.

Based on these results, the team concluded that the agreement between the PCI device and the manual keratometers was excellent and therefore, the PCI device can be used for toric IOL calculations.

For further information please view the abstract in the Journal of Cataract & Refractive Surgery.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.